HROW
Harrow Inc
NASDAQ · Pharmaceuticals
$47.32
+1.26 (+2.74%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 207.38M | 147.95M | 741.62M | 753.50M | 775.29M |
| Net Income | -18,159,463 | -11,659,782 | 118.74M | 117.60M | 129.68M |
| EPS | — | — | — | — | — |
| Profit Margin | -8.8% | -8.3% | 16.0% | 15.6% | 16.7% |
| Rev Growth | +40.2% | +40.2% | +13.7% | +23.8% | +22.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 665.24M | 665.24M | 853.97M | 692.61M | 691.25M |
| Total Equity | 211.06M | 211.06M | 1.27B | 1.12B | 1.10B |
| D/E Ratio | 3.15 | 3.15 | 0.67 | 0.62 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 10.90M | 7.39M | 202.60M | 185.25M | 214.55M |
| Free Cash Flow | — | — | 69.51M | 80.89M | 86.69M |